Skip to main content
. Author manuscript; available in PMC: 2024 May 15.
Published in final edited form as: JCO Precis Oncol. 2024 Apr;8:e2300635. doi: 10.1200/PO.23.00635

TABLE 2.

Summary of Statistical Analysis of OS

Population Methodology OS Hazard Ratio (90% CI) Gemcitabine/Berzosertib v Gemcitabine Alone
Overall ITT 0.79 (0.52 to 1.20)
Exclude crossover 0.60 (0.38 to 0.94)
CXO 0.73 (0.47 to 1.15)
TVC 0.81 (0.55 to 1.20)
IPCW 0.58 (0.37 to 0.89)
PFI ≤3 months ITT 0.48 (0.22 to 1.01)
Exclude crossover 0.26 (0.11 to 0.62)
CXO 0.33 (0.13 to 0.83)
TVC 0.59 (0.29 to 1.21)
IPCW 0.29 (0.12 to 0.70)
ATM-negative/ATM-low ITT 0.50 (0.23 to 1.08)
Exclude crossover 0.32 (0.14 to 0.73)
CXO 0.43 (0.19 to 0.96)
TVC 0.60 (0.29 to 1.22)
IPCW 0.34 (0.16 to 0.72)
RS-low ITT 0.77 (0.40 to 1.49)
Exclude crossover 0.39 (0.19 to 0.82)
CXO 0.60 (0.27 to 1.33)
TVC 0.57 (0.31 to 1.08)
IPCW 0.49 (0.23 to 1.04)

Abbreviations: CXO, censored at crossover; IPCW, inverse probability of censor weighting; ITT, intent-to-treat; OS, overall survival; PFI, platinum-free interval; RS, replication stress; TVC, time-varying covariate.